Watch JBIO. Know when insiders buy.
One email the day a filing lands. Free.
JBIO
Jade Biosciences, Inc.
16.94
−0.20 −1.17%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
41
WATCH · shorts 41
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.1BP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$153.2MNET CASH —52W 7.61 – 26.85SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$58.9M | −$55.8M | — | -0.76 | −$43.7M | — | — | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | −$43.4M | −$40.4M | — | -0.57 | −$24.1M | — | — | Aug 10 |
| Q4 2025 · Dec 31derived | — | — | — | −$35M | −$31.9M | — | -0.11 | −$33.6M | $3K | −$33.7M | Mar 6 |
| Q3 2025 · Sep 30 | — | — | — | −$27.4M | −$25.2M | — | -0.48 | −$22.1M | $57K | −$22.2M | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$27.8M | −$32.1M | — | -0.86 | −$20.2M | — | — | Aug 10 |
| Q1 2025 · Mar 31 | — | — | — | −$23.4M | −$38.2M | — | -12.10 | −$18.8M | — | — | Aug 10 |
| Q4 2024 · Dec 31derived | — | — | — | −$6.4M | −$5.4M | — | -0.19 | −$11M | — | — | Mar 27 |
| Q3 2024 · Sep 30 | — | — | — | −$15.6M | −$16.9M | — | -5.35 | −$6.8M | — | — | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$26.2M | −$24.8M | — | -0.86 | −$20.4M | — | — | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$24.6M | −$23.2M | — | -0.83 | −$23.7M | — | — | Apr 25 |
| Q4 2023 · Dec 31derived | — | — | — | −$22.1M | −$20.4M | — | -0.74 | −$14.8M | $64K | −$14.9M | Mar 27 |
| Q3 2023 · Sep 30 | — | — | — | −$21.4M | −$19.6M | — | -0.71 | −$15.6M | $32K | −$15.6M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$113.5M | −$127.4M | — | -3.19 | −$94.7M | $196K | −$94.9M | — | — |
| FY2024 · to Dec 31 | — | — | −$74.6M | −$69.6M | — | -2.44 | −$71.2M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$81.4M | −$75.5M | — | -2.87 | −$56.8M | $142K | −$56.9M | — | — |
| FY2022 · to Dec 31 | — | — | −$53.2M | −$51.5M | — | -2.10 | −$39.1M | $195K | −$39.3M | — | — |
| FY2021 · to Dec 31 | — | — | −$23M | −$23M | — | -1.87 | −$27.4M | $181K | −$27.6M | — | — |
| FY2020 · to Dec 31 | — | — | −$8.9M | −$9.6M | — | -40.31 | −$7.9M | — | — | — | — |
Every number comes from Jade Biosciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.